1. Home
  2. ELWS vs SLXN Comparison

ELWS vs SLXN Comparison

Compare ELWS & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELWS
  • SLXN
  • Stock Information
  • Founded
  • ELWS 2018
  • SLXN 2008
  • Country
  • ELWS Japan
  • SLXN Israel
  • Employees
  • ELWS N/A
  • SLXN N/A
  • Industry
  • ELWS
  • SLXN
  • Sector
  • ELWS
  • SLXN
  • Exchange
  • ELWS Nasdaq
  • SLXN NYSE
  • Market Cap
  • ELWS 6.0M
  • SLXN 6.9M
  • IPO Year
  • ELWS 2023
  • SLXN N/A
  • Fundamental
  • Price
  • ELWS $1.90
  • SLXN $0.92
  • Analyst Decision
  • ELWS
  • SLXN Strong Buy
  • Analyst Count
  • ELWS 0
  • SLXN 1
  • Target Price
  • ELWS N/A
  • SLXN $5.00
  • AVG Volume (30 Days)
  • ELWS 187.7K
  • SLXN 3.6M
  • Earning Date
  • ELWS 06-03-2025
  • SLXN 05-13-2025
  • Dividend Yield
  • ELWS N/A
  • SLXN N/A
  • EPS Growth
  • ELWS N/A
  • SLXN N/A
  • EPS
  • ELWS N/A
  • SLXN N/A
  • Revenue
  • ELWS $2,292,406.00
  • SLXN N/A
  • Revenue This Year
  • ELWS N/A
  • SLXN N/A
  • Revenue Next Year
  • ELWS N/A
  • SLXN N/A
  • P/E Ratio
  • ELWS N/A
  • SLXN N/A
  • Revenue Growth
  • ELWS 404.13
  • SLXN N/A
  • 52 Week Low
  • ELWS $1.04
  • SLXN $0.21
  • 52 Week High
  • ELWS $8.68
  • SLXN $13.56
  • Technical
  • Relative Strength Index (RSI)
  • ELWS 46.25
  • SLXN N/A
  • Support Level
  • ELWS $1.78
  • SLXN N/A
  • Resistance Level
  • ELWS $3.67
  • SLXN N/A
  • Average True Range (ATR)
  • ELWS 0.30
  • SLXN 0.00
  • MACD
  • ELWS 0.01
  • SLXN 0.00
  • Stochastic Oscillator
  • ELWS 6.08
  • SLXN 0.00

About ELWS Earlyworks Co. Ltd.

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Share on Social Networks: